| INTRODUCTION
Neuroblastoma accounts for 8-10% of all childhood cancers with an annual incidence of ∼1 in 10,000 children less than 15 years of age in the United States.
1,2 Over 60% of neuroblastoma tumors are highly metastatic and exhibit a high rate of relapse. 3 This type of neuroblastoma exhibits poor prognosis with cytogenetic features, including chromosomal instability and amplification of the N-MYC gene. 1, 3 The differentiation stage of neuroblastoma is the most common measure of tumor aggressiveness. 4 Thus, the current standard of care typically utilizes differentiation-inducing agents, such as retinoids, immunotherapy, or small molecule inhibitors of the cell cycle. 5 The sensitivity to therapeutic interventions is dependent on several key factors including amplification of N-MYC and TP53
status. 5 Interestingly, among resistant neuroblastomas, differences in the sensitivity to atRA can also be significant, and the mechanism underlying this variability is unknown. Thus, there remains a need to elucidate the mechanisms that mediate the differences observed in the inhibition of neuroblastoma tumorigenicity by selective agents in order to develop new therapeutic approaches for this disease.
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) dynamically heterodimerizes with retinoid X receptor (RXR) by ligand activation, and regulates expression of target genes that modulate cell proliferation, differentiation, inflammation, and lipid and glucose homeostasis. 6 The role of PPARβ/δ in carcinogenesis remains controversial as some studies suggest that activating PPARβ/δ promotes tumorigenesis, while others suggest the opposite. 6, 7 Recently, several studies have revealed that over-expression of PPARβ/δ inhibits tumorigenesis in different types of human cancer types including breast, colon, and testis. [8] [9] [10] These studies are similar to results showing that knockdown of PPARβ/δ promotes tumorigenesis in human colon cancer models, an effect that is mediated in part by inhibition of induction of terminal differentiation. [11] [12] [13] This is of interest to note because it is firmly established that PPARβ/δ promotes terminal differentiation in multiple cell types. 14, 15 Induction of terminal differentiation is one approach used for cancer therapy, 16, 17 including neuroblastoma patients. 18 This is particularly true for high-risk neuroblastoma patients and can be accomplished by treatment with retinoic acid to induce terminal differentiation of neuroblastoma cells. [19] [20] [21] [22] [23] [24] It was recently hypothesized that atRA may promote tumorigenesis by alternatively activating PPARβ/δ, rather than retinoic acid receptors, based on the ratio of cellular retinoic acid binding protein-II and fatty acid binding protein-5. 25 However, this hypothetical mechanism is not consistently observed [26] [27] [28] and should be carefully re-evaluated. 6, 7, 29 Since previous studies revealed that PPARβ/δ-induced differentiation inhibits tumorigenesis, 6, 7, 14 the hypothesis that over-expressing and/or activating PPARβ/δ modulates tumorigenesis of human N-MYC-amplified neuroblastoma cells was examined in this study. Further, the effect of relative expression of PPARβ/δ on atRA-induced differentiation of retinoic acid-sensitive and -insensitive human neuroblastoma cells lines was examined.
| MATERIALS AND METHODS

| Cell culture
The human neuroblastoma cell lines, NGP, SK-N-BE(2), and IMR-32
(American Type Culture Collection) were cultured in Dulbecco's modified Eagle's media (DMEM, Cellgro, Manassas, VA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Invitrogen, Grand Island, NY) at 37°C with 5% carbon dioxide.
| Stable human neuroblastoma cells over-expressing hPPARβ/δ
Stable NGP, SK-N-BE(2), and IMR-32 cell lines were produced that express the enhanced green fluorescent protein (eGFP) or eGFP and the human PPARβ/δ (hPPARβ/δ). 9 Expression of eGFP and hPPARβ/δ was verified as previously described. 8, 9 Cells were treated with or without 0.01-1.0 μM GW0742 (a specific PPARβ/δ agonist 30 ), 1 μM DG172 (a selective repressive PPARβ/δ ligand 31 ) or 10 μM atRA; an RAR agonist, Sigma-Aldrich, St. Louis, MO) as described below.
| Western blot analysis
Quantitative western blot analysis was performed with radioactive detection as previously described. 9 The expression level of nuclear proteins was normalized to TBP, and the expression level of cytosolic protein was normalized to LDH.
| Quantitative real-time polymerase chain reaction (qPCR)
Gene expression was measured by qPCR analysis as previously described. 32 Relative mRNA levels were normalized to the mRNA level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
| Cell proliferation assay
The xCELLigence system (ACEA Biosciences, Inc. San Diego, CA) was used for quantifying changes in real-time cell proliferation in NGP and SK-N-BE(2) cells as previously described. 
| Chromatin immunoprecipitation (ChIP)-qPCR
Putative trans-acting factors in each region of SOX2 promoter were identified using the ConSite program. 33 To confirm occupancy of trans-acting factors on the SOX2 promoter, ChIP-qPCR was performed to quantify relative promoter occupancy in response to overexpression of PPARβ/δ as previously described. 9 Antibodies against SP1, p65, YY1 (Santa Cruz Biotechnology, Santa Cruz, CA), MYC, and AP-2γ (Cell Signaling Technology, Danvers, MA) were individually added to histone-DNA complexes for immunoprecipitation of protein bound chromatin. The relative level of occupied SOX2 promoter in each group was normalized to IgG input control.
| Statistical analyses
All experimental groups were performed in triplicate and repeated using three independent biological replicates. The data were subjected to Student's t-test or a parametric one-way analysis of variance (ANOVA) followed by Tukey test for post hoc comparisons. Statistical significance was considered when P ≤ 0.05. (Fig. 4A) . By contrast, DG172 treatment down-regulated ADRP mRNA expression in all three neuroblastoma cell lines (Fig. 4A) . Activation of RARα with atRA had no effect on ADRP mRNA expression in all three neuroblastoma cell lines (Fig. 4A) . Interestingly, over-expression of PPARβ/δ up-regulated TP53 mRNA expression in IMR-32 cells, but not in NGP or SK-N-BE (2) cells (Fig. 4B ). Ligand activation of PPARβ/δ with GW0742 induced TP53 mRNA expression in IMR-32-MigR1 cells, but not in NGP or SK-N-BE(2) cells (Fig. 4B ). DG172-decreased TP53 mRNA expression was also found in IMR-32-hPPARβ/δ cells, but not in NGP or SK-N-BE (2) cells (Fig. 4B) . Activation of RARα with atRA induced TP53 mRNA expression in both NGP-MigR1 and NGP-hPPARβ/δ cells; however, no significant difference was detected between these two groups (Fig. 4B) . By contrast, activation of RARα with atRA had no effect on TP53 mRNA expression in SK-N-BE(2) or IMR-32 cells (Fig. 4B) . Since p53 is known to increase PTEN expression, 39 it is important to note that over-expression of PPARβ/δ caused an increase in PTEN mRNA expression in NGP-hPPARβ/δ and IMR-32-hPPARβ/δ cells compared to controls, but not in SK-N-BE(2)-hPPARβ/δ cells (Fig. 4C) . Neither ligand activation nor selective repression of PPARβ/δ influenced PTEN mRNA expression in all three neuroblastoma cell lines (Fig. 4C) . (Fig. 4C ).
| PPARβ/δ inhibits ectopic tumor xenografts by induction of differentiation, necrosis, and infiltration of inflammatory cells
The average tumor volume and weight of ectopic xenografts from
SK-N-BE(2)-MigR1 and IMR-32-MigR1 cells was comparatively
smaller than those from NGP-MigR1 cells (Fig. 5A and B ). This correlated with higher level of necrosis in xenografts from (Fig. S3) . 3.5 | PPARβ/δ-dependent down-regulation of SOX2 is mediated by altered YY1, SP1 and AP-2γ activities in neuroblastoma cells
To identify the regulatory region in the SOX2 promoter required for mediating PPARβ/δ-dependent down-regulation of SOX2 expression, three luciferase reporter constructs (P1300, P1000, and P500) of the human SOX2 promoter (−1 to −1300, −1 to −1000, and −1 to −500, respectively) were generated (Fig. 6A) , and transfected into control and PPARβ/δ over-expressing NGP and IMR-32 cells because they represent atRA sensitive (NGP) and atRA insensitive (IMR-32) cell lines. The data from these analyses indicate that the region from −1 to −1000 is critical for PPARβ/δ-dependent repression of SOX2
promoter activity in both of these cell lines, but this effect was more pronounced in the IMR-32 cell line (Fig. 6B) . Putative cisregulatory elements in this region of the SOX2 promoter included binding sites for YY1, AP-2γ, SP1, and MYC (Fig. 6A ).
ChIP assays revealed increased promoter occupancy of SP1 and reduced promoter occupancy of YY1 in the −1 to −500 region of the SOX2 promoter in NGP-hPPARβ/δ and IMR-32-hPPARβ/δ cells compared to controls (Fig. 6C) . Greater promoter occupancy of AP-2γ in this region of the SOX2 promoter was also detected in NGPhPPARβ/δ cells, but not in IMR-32-hPPARβ/δ cells compared to controls (Fig. 6C) . Increased promoter occupancy of SP1 and AP-2γ, together with decreased promoter occupancy of YY1 in the −500 to −1000 region of the SOX2 promoter was observed in IMR-32 cells over-expressing PPARβ/δ (Fig. 6D) ; while NGP-hPPARβ/δ cells exhibited greater promoter occupancy of AP-2γ compared to controls (Fig. 6D) . Quantitative western blot analysis further confirmed higher expression of SP1 and AP-2γ, and lower expression YY1 in nuclear fractions of NGP-hPPARβ/δ and IMR-32-hPPARβ/δ cells compared to controls (Fig. 6E ). These observations suggest that PPARβ/δ-dependent activation of SP1 and/or AP-2γ together with PPARβ/δ-dependent inhibition of YY1 may co-operatively mediate downregulation of SOX2 expression in neuroblastoma cells. Transcriptional regulation of SOX2 has been evaluated in human and mouse embryonic stem cells. 47, 48 The present study revealed novel regulation of SOX2 expression is mediated by modulating SP1, YY1, and AP-2γ activities in neuroblastoma cells through a mechanism that requires PPARβ/δ. SP1 acts as a transcription factor by interacting with GC-rich sequences of target gene promoters, especially for genes driven by a TATA-box-less promoter. 49 Multiple putative SP1 binding sites were identified in the SOX2 promoter, a TATA-box-less promoter indeed, supporting the notion that SP1 co-operates with PPARβ/δ in regulating SOX2 expression. This is consistent with previous studies demonstrating that SP1 is critical in PPARβ/δ-dependent signaling, 50 and negatively regulates the pluripotency in stem cells by targeting OCT4 and NANOG. [51] [52] [53] This is consistent with previous studies
showing that SP1 represses transcription in human cancer cells. 54, 55 Over-expression of PPARβ/δ caused nuclear accumulation of SP1 associated with a greater occupancy of SP1 in SOX2 promoter in neuroblastoma cells. This suggests that SP1 is likely required for PPARβ/δ-dependent suppression of SOX2 expression by directly binding to SOX2 promoter as a transcription repressor but this hypothesis requires further studies. Similar to SP1, AP-2γ also reveals a critical role in cell differentiation by suppressing stem cell marker expression. 56 These observations are also collectively similar to previous studies showing that PPARβ/δ require co-recruitment of other transcription factors for optimal modulation of gene expression. 57 The present study also showed that YY1 expression in the nuclear fraction was decreased in neuroblastoma cell over-expressing PPARβ/ δ, and these cells exhibited less YY1 occupancy on the SOX2 promoter.
This suggests that PPARβ/δ may attenuate YY1-induced SOX2 expression in neuroblastoma cells. Additionally, YY1 is known to repress SP1-mediated transcriptional regulation. 58 This suggests that PPARβ/δ-dependent activation of SP1 and PPARβ/δ-dependent inactivation of YY1 co-operatively inhibit SOX2 expression in neuroblastoma cells. It is worth noting that the alteration of SP1
and YY1 occupancy in −500 to −1000 region of SOX2 promoter was not observed in retinoic acid-sensitive neuroblastoma NGP cells overexpressing PPARβ/δ. The mechanism underlying this difference cannot be determined from these studies but could be due to differences in the expression patterns of other co-effector proteins that modify chromatin and allow PPARβ/δ to alter gene expression.
Further studies are needed to examine this hypothesis. 
